Sensyne Health Share Discussion Threads

[billy3] 30/9/2020 14:48

RNS Number : 6245A
Sensyne Health PLC
30 September 2020


Sensyne Health announces collaboration with the University of Oxford to provide software for remote symptom data collection and analytics for a Phase II clinical trial in care homes of adalimumab to prevent respiratory failure due to COVID-19





Highlights :

· Sensyne's software for remote symptom data collection and analytics will support researchers in academia and the pharmaceutical industry to undertake clinical trials during the pandemic, particularly within the community environment

· Collaboration with the University of Oxford for the AVID-CC Phase II clinical trial in care homes of the anti-TNF drug adalimumab funded by the Wellcome Trust

· Further agreements to use Sensyne's capabilities in other clinical trials are in advanced discussions



Oxford, U.K. 30 September 2020: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the UK Clinical AI company, today announces a collaboration with the University of Oxford in which Sensyne will provide software for remote data collection and analytics for the AVID-CC Phase II clinical trial of the anti-TNF drug adalimumab to prevent respiratory failure due to COVID-19. The trial is funded by the COVID-19 Therapeutics Accelerator, an initiative set up by the Wellcome Trust, the Bill and Melinda Gates Foundation and Mastercard, with support from an array of public and philanthropic donors.



The purpose of the trial is to assess the effectiveness of Adalimumab in preventing progression to respiratory failure or death due to COVID-19 infection. A particular feature of this trial, supported by Sensyne's software, is the remote collection of data on symptoms, vital signs and activities of daily living from clinical trial subjects in care homes, followed by a phase of exploratory data analysis using Sensyne's machine learning algorithms.



The software is based on Sensyne's CVm-Health ™ software application for tracking COVID-19 symptoms launched earlier this year. The use of CVm-Health will allow clinical trial participants in care homes to record their symptoms and vital signs and enable trial investigators to access such data remotely. The 'Good Neighbour' aspect of CVm-Health, whereby a carer, with consent, can enter data on behalf of an individual, is an important feature that facilitates clinical trials in the community care environment. Under the trial protocol, and with the consent of participants, anonymised data recorded by the application during the trial will be analysed using machine learning algorithms developed by Sensyne.



Sensyne is in advanced discussions for the use of its remote symptom and vital sign data collection software and analytics expertise by other clinical researchers seeking to undertake drug trials during the COVID-19 pandemic, particularly trials within community settings such as care homes. Further announcements will be made as such discussions reach agreement.





Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

"Sensyne is at the forefront of developing advanced remote monitoring software and clinical AI tools that enable clinical research to be undertaken during the new circumstances caused by the COVID-19 pandemic. We are delighted to be working with the University of Oxford on this important new trial of Adalimumab , pioneering new clinical research techniques in the community environment."





Professor Duncan Richards FRCP, Climax Professor of Clinical Therapeutics and Director of the Oxford Clinical Trials Research Unit (OCTRU), formerly Head of Clinical Pharmacology and Experimental Medicine for GSK (until 2019), who is the Chief Investigator for the AVID-CC trial , said:

" We have been impressed by Sensyne Health's digital health and clinical AI capabilities. We are excited by the opportunity that that flexible electronic diaries for remote data collection and analytics, such as CVm-Health for patients and carers to contribute to information collected in clinical trials. This pandemic has highlighted the need to re-examine the ways in which we collect data. We are delighted to be working with Sensyne and are excited by the potential for unique insights that may come from exploratory analyses of the anonymised clinical trial data using their proprietary machine learning algorithms."





-ENDS-

[billy3] 30/9/2020 14:47

Sensyne Health losses deepen on higher R&D spend

30 September 2020, 09:06
Source - SMW

Healthcare technology group Sensyne Health posted a deeper annual loss amid a rise in R&D spending.

Pre-tax losses for the year through April amounted to £22.6 million, compared to losses of £19.0 million year-on-year. Revenue rose to £2.1 million, up from £0.1 million.

Operational highlights during the year included the signing of agreements with Cognizant and Agorai as partners for the sale of digital health software products in the US.

The company also signed is first major pharmaceutical collaboration agreement for £5 million with Bayer to accelerate the development of new treatments for stroke and cardiovascular disease using clinical artificial intelligence.

'Sensyne has made significant commercial and technological progress in the past 12 months, despite a number of challenges and the dramatic changes triggered by Covid-19,' chief executive Paul Drayson said.

'I am particularly proud of how the company has developed solutions to some of the challenges that have arisen during the course of the pandemic.'

'Sensyne's achievements over the past year highlight the dedication and proficiency of our employees who are committed to supporting the company's mission to improve patient care and accelerate pharmaceutical research.'

'Recent developments have underlined the growth potential that our model can deliver as healthcare moves towards wider adoption of clinical AI and remote patient monitoring.'

[rambutan2] 29/9/2020 15:17

At last!

Oxford, U.K. 29 September 2020 : Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company"), the UK Clinical AI company, notes that on 5 June 2020, Acacia Research Corporation (Nasdaq: ACTG) announced that it had entered into an agreement with Link Fund Solutions Limited ("LFS") to purchase shares in a number of public and private life sciences companies from the LF Equity Income Fund which was previously managed by Woodford Investment Management Limited.

The agreement was structured to take ownership of portfolio positions in a staged manner. Sensyne Health welcomes Acacia Research as an 11.8% shareholder and the clarity brought to the market with this announcement for the previously anticipated share transfer.

Clifford Press, CEO of Acacia Research , commented:

" We recognise the extraordinary potential of Sensyne's business model as conceived and implemented by Lord Drayson. As governance-oriented investors, we are impressed by the constructive manner in which Sensyne has engaged with us as a major shareholder. We strongly support the continued development of a very talented management team for the next stage of the Company's growth."

[billy3] 29/9/2020 08:58

Full year results are tomorrow


Notice of Full Year Results

Oxford, UK; 23 September 2020: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company") , the Clinical AI company, will announce its Full Year Results for the 12 months ended 30 April 2020 on Wednesday 30th September 2020.

Lord (Paul) Drayson, Chief Executive Officer, and Michael Norris, Interim Chief Financial Officer, will host a virtual briefing for analysts and investors at 14.00 BST on the day of the results.

Details of the webcast, and the presentation slides, will be available via the Company website. For more details please contact [e-mail].


-ENDS-

[billy3] 18/9/2020 09:48

Must be results time soon.....in the next few weeks same as last year ?

[edwardt] 10/9/2020 17:26

Somewhat perplexed shares fluid not respond well. Guess he may have bucket load of free options to join....

[rambutan2] 10/9/2020 12:57

A BIG tick:

Oxford, U.K. 10 September 2020 : Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the UK Clinical AI company, announces that it has appointed Michael Macdonnell to its senior management team as Chief Operating Officer (COO) reporting to the CEO Lord Drayson. Michael will join Sensyne with effect from 28 September 2020.

Michael is currently Director of Global Deployment at Google Health, which he joined from Google DeepMind. Prior to joining Google, Michael was National Director of System Transformation and Director of Strategy at NHS England where he oversaw the delivery of key strategic initiatives including the NHS Five Year Forward View and the development of integrated care systems.

Previously, Michael has held roles at Accenture, the Centre for Health Policy, Imperial College London and as an advisor at the Prime Minister's Delivery Unit.

Michael remains an honorary fellow at the Institute of Global Health Innovation, Imperial College London, and is a Policy Fellow at the Centre for Science and Policy, University of Cambridge.

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

"Michael brings deep healthcare expertise and a strong track-record of driving healthcare improvements through the application of advanced technology. His experience of applying artificial intelligence to real-world research and clinical practice, in collaboration with both NHS and US-based healthcare providers, will be crucial in helping Sensyne to grow to its next stage of development. Importantly, he also strongly values social purpose, which matches Sensyne's unique business model and ethical approach to the use of clinical AI."

Michael Macdonnell, said:

"Sensyne is an exceptional opportunity: a company that combines social impact with the capabilities to effect real change in how healthcare is delivered. Data insights and digital therapeutics could bring about an era of proactive or anticipatory care and disrupt a model of medicine too often based on the average patient. By working and sharing value with our healthcare partners, we can build a game-changing portfolio of technologies that will improve care for patients in the NHS and around the world."

[zulu_principle] 10/9/2020 08:35

Back in with a small purchase for the long term. Looks like a very good hire - much more interesting than the recent vapourware announcements which (to my mind) have been high on hyperbole but woefully lacking in specifics. Time to sit back and wait.

[edwardt] 10/9/2020 07:48

Belter of a hire.

[mrc2u] 10/9/2020 07:09

New COO looks like top notch hire and good to see them strengthening the management team. No doubt a degree of succession planning tooShares looking like a bargainMrC

[edwardt] 09/9/2020 13:03

interesting to see emis entering the analytics market in order to help the NHS to 'interpret their data'. they also mention M&A - someone should give them Drayson's numberl. lol.

[sos100] 03/9/2020 07:55

excellant rns

[mrc2u] 03/9/2020 07:45

Yes, very positive: they have got a new product to market in partnership with a world leading hospital and world leading tech company. And done it in less than 6 months (I assume) and have more in the pipeline. This indicates they can have a lot of products quickly, some of which ought to fly and few really flyImpressiveMrC

[parvez] 03/9/2020 07:15

SENSE partnership with Microsoft bodes well

[rambutan2] 31/8/2020 21:50

A big winner Stateside during the pandemic. Quite different, but shares some similarities...

[cokehookerscars] 28/8/2020 15:54

" just feel sorry for Woodford investors. The regulator should be ashamed of themselves."

Yep :-(

[billy3] 28/8/2020 14:23

Plenty of buys today and a move back up to where the week started.
These sort of days are always suspicious.....so is it another announcement or a share tip in the Sunday papers ?

[mally6] 25/8/2020 16:11

TIME TO BUY BACK IN

[newtoaim] 25/8/2020 13:05

The pump her took it to 90p before the dump

[volsung] 24/8/2020 16:24

Bought a few more on the dip

[billy3] 21/8/2020 17:50

I’m sure you’ll be fine long term. It’s been an interesting week. Last week the movement suggested something was going on and I commented so. It was a nice rise this week on news. The market for the new app will be huge if successful.

The last couple of days we have seen some ‘distribution’ of shares with some sellers either taking profit or even selling at a Smaller loss thinking they don’t want to see 28p again. Current price isn’t bad and at least we didn't sell off again. Support was there around 60p.

I see the next moves if we get a Sunday paper recommendation and / or news with Official results in the next month or so.

I’m tempted if we get back to around 80p to start trading this share instead of holding. My background is not quite day trading but have held Shares for minutes or hours to sell at a profit. I spread bet and have been for about 20 years. But held SENS since Oct last year and topped up along the way. Taken profit once and rebought.
Selling then buying back after a 10% drop in this share may be very profitable. The risk is selling then not seeing it fall back to purchase again. So we need more of a chart to see support and resistance. This share is closely held by institutions and people like Drayson. So retail punters like us can have quite an effect on the price as we saw Wednesday.

In the meantime, I’m happy to hold as once we breach Wednesdays price we should get over £1. As above, I’m sure there is more news they are keeping for results. Now we have seen what news can do, I’m feeling much more confident with my position. It would be great to know the real time breakdown of what institutions are holding.

[edwardt] 20/8/2020 10:06

Changing your mind is no sin in my mind. Fail fast as the yanks say.